Plerixafor

Plerixafor

SCHEMBL19038

c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CXCR4

The experimentally established mechanism targets of Plerixafor. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CXCR4 known ✓ P61073 16/20 1.00
HRH3 Q9Y5N1 2/20 1.00
MEN1 O00255 1/20 1.00
CHRM2 P08172 1/20 1.00
CHRM1 P11229 1/20 1.00
ADRA2C P18825 1/20 1.00
CCR2 P41597 1/20 1.00
CXCL12 P48061 1/20 1.00
BLM P54132 1/20 1.00
KMT2A Q03164 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
SIGMAR1 Q99720 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5611617 1.00 CXCR4 (1.00) CXCR4HRH3MEN1CHRM2CHRM1
SCHEMBL29490414 1.00 CXCR4 (1.00) CXCR4HRH3MEN1CHRM2CHRM1
Hydrochloric Acid SCHEMBL7610931 0.98 CXCR4 (1.00) CXCR4HRH3MEN1CHRM2CHRM1
Hydrochloric Acid SCHEMBL7612104 0.98 CXCR4 (1.00) CXCR4HRH3MEN1CHRM2CHRM1
Plerixafor SCHEMBL414153 0.98 CXCR4 (1.00) CXCR4HRH3MEN1CHRM2CHRM1
Plerixafor SCHEMBL6889125 0.98 CXCR4 (1.00) CXCR4HRH3MEN1CHRM2CHRM1
Plerixafor SCHEMBL123040 0.96 CXCR4 (1.00) CXCR4HRH3MEN1CHRM2CHRM1
Plerixafor SCHEMBL1649655 0.96 CXCR4 (0.93) CXCR4HRH3MEN1CHRM2CHRM1
SCHEMBL14065686 0.96 CXCR4 (0.93) CXCR4HRH3MEN1CHRM2CHRM1
Plerixafor SCHEMBL5680189 0.96 CXCR4 (0.93) CXCR4HRH3MEN1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 12342 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144823-A1 COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANT SPACECRAFT SEVEN, LLC (US) 2026-05-28 US claimed
US-20260137727-A1 PREVENTION AND TREATMENT OF KIDNEY FAILURE BY ADMINISTRATION OF FIBROBLASTS AND PRODUCTS THEREOF SPINALCYTE LLC (US) 2026-05-21 US claimed
EP-4743077-A2 METHODS FOR DOWN-REGULATION AND UP-REGULATION OF PATHWAYS Medregen, LLC (US) 2026-05-20 EP claimed
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
CN-122057015-A Cell therapeutic preparation based on tumor specific antigen and application of cell therapeutic preparation in solid tumor 臻辉生物技术(河南)有限公司 2026-05-19 CN claimed
WO-2026099526-A1 COMBINATION OF INHIBITORS OF IL-1BETA, CCR5 OR CXCR2 CYTOKINE RECEPTORS FOR USE IN THE TREATMENT OF METASTASIS FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (ES) 2026-05-15 WO claimed
US-20260132141-A1 PROTEIN PHOSPHATASE 2A ACTIVATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2026-05-14 US claimed
US-12605445-B2 Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2026-04-21 US claimed
EP-4724096-A1 GPCR INHIBITORS AND USES THEREOF GPCR Therapeutics, Inc. (KR) 2026-04-15 EP claimed
EP-4724503-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS THROUGH INHIBITION OF CELL-IN-CELL PHENOMENON Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) 2026-04-15 EP claimed
EP-0823902-A1 PROCESS FOR PREPARING 1,1'- 1,4-PHENYLENEBIS-(METHYLENE)]-BIS-1,4,8,11-TETRAAZACYCLOTETRADECANE JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 1998-02-18 EP claimed
EP-0817777-A1 PROCESS FOR PREPARING 1,1'- 1,4-PHENYLENEBIS-(METHYLENE)]-BIS-1,4,8,11-TETRAAZACYCLOTETRADECANE JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 1998-01-14 EP claimed
US-5612478-A Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane JOHNSON MATTHEY PLC (GB) 1997-03-18 US claimed
US-5606053-A Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane JOHNSON MATTHEY PLC (GB) 1997-02-25 US claimed
US-5583131-A FOR TREATMENT OR PREVENTION OF ACQUIRED IMMUNE DEFICIENCY SYNDROME, REDUCED TOXICITY JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 1996-12-10 US claimed
WO-1996034860-A1 PROCESS FOR PREPARING 1,1'-[1,4-PHENYLENEBIS-(METHYLENE)]-BIS-1,4,8,11-TETRAAZACYCLOTETRADECANE JOHNSON MATTHEY PLC (GB) 1996-11-07 WO claimed
WO-1996030349-A1 PROCESS FOR PREPARING 1,1'-[1,4-PHENYLENEBIS-(METHYLENE)]-BIS-1,4,8,11-TETRAAZACYCLOTETRADECANE JOHNSON MATTHEY PLC (GB) 1996-10-03 WO claimed
EP-0619813-A1 LINKED CYCLIC POLYAMINES WITH ACTIVITY AGAINST HIV JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 1994-10-19 EP claimed
WO-1993012096-A1 LINKED CYCLIC POLYAMINES WITH ACTIVITY AGAINST HIV JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 1993-06-24 WO claimed
US-4661600-A Manufacture of 2-oxazolines, 2-oxazines, 2-imidazolines and 2-imidazines ASHLAND OIL, INC. (US) 1987-04-28 US claimed